The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Mineralys Therapeutics to take part in Goldman Sachs 47th Annual Global Healthcare fireside chat
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 8, 4:44 PM EDT

Mineralys Therapeutics to take part in Goldman Sachs 47th Annual Global Healthcare fireside chat

Management at Mineralys Therapeutics (MLYS) is scheduled to discuss the company’s hypertension drug program during the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, with a fireside chat set for June 9 at 2:40 p.m. ET.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Mineralys Therapeutics, Inc. said it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, a major healthcare investor event, as the company advances its aldosterone-focused drug program for hypertension and related conditions. The company announced on June 8, 2026 that its management will take part in the conference in Miami from June 8 to June 10, with a fireside chat scheduled for Tuesday, June 9 at 2:40 p.m. ET.

Mineralys Therapeutics is a biopharmaceutical company focused on diseases driven by dysregulated aldosterone. In investor materials, it describes lorundrostat as its initial product candidate, an orally administered, highly selective aldosterone synthase inhibitor, aimed at treating hypertension and comorbidities including chronic kidney disease and obstructive sleep apnea.

The conference appearance comes after Mineralys reported a key regulatory milestone for lorundrostat. In a March 12, 2026 update, the company said the U.S. Food and Drug Administration accepted its new drug application (NDA) for lorundrostat in adults with hypertension and set a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

Mineralys has also been financing the work needed to move lorundrostat through the FDA process. In a June 3, 2026 press release, the company said it priced an underwritten offering of 5,660,378 shares of common stock at $26.50 per share, expecting gross proceeds of about $150.0 million. The company said it intends to use net proceeds to help fund a $200.0 million upfront payment to repurchase royalty obligations under a license agreement with Tanabe Pharma Corporation.

As biotech companies approach major regulatory decision points, investor conferences often serve as a forum to reinforce development narratives, address timelines, and provide management perspective on what investors should watch next. The fireside chat format, rather than a formal slide presentation alone, typically allows follow-up discussion that can shape near-term expectations for market participants as they await later-stage trial outcomes and regulatory updates.

The June 8 announcement did not provide additional lorundrostat trial data, changes to the NDA timeline, or new guidance beyond confirming the company’s planned participation, the date, the time, and the fireside chat format. It also did not specify which individual(s) from management would participate in the session in the text of the announcement.

What to watch next is whether the June 9 webcast and any subsequent follow-up communications offer further detail on the FDA review process, the state of lorundrostat commercialization planning, or how Mineralys is thinking about remaining scientific or operational milestones. With a December 22, 2026 PDUFA target date already in place, the company’s conference commentary may be closely scrutinized for any indicates about progress and risks ahead of that decision.

Why It Matters

  • The conference gives Mineralys a platform to communicate near-term priorities and investor expectations during a period leading into the FDA review timeline.
  • Because lorundrostat’s NDA has a December 22, 2026 PDUFA target date, management commentary at the event may influence sentiment around regulatory progress and risk.
  • The fireside chat format can provide more context than a standard investor update, potentially affecting how investors interpret forthcoming milestones.
  • Recent financing activity indicates that Mineralys is continuing to fund development and regulatory work while preparing for possible commercialization paths.

Sources

Key Facts

  • Mineralys Therapeutics said management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.
  • The company’s fireside chat is scheduled for Tuesday, June 9, 2026 at 2:40 p.m. ET.
  • Mineralys’ initial product candidate, lorundrostat, is described as an orally administered, highly selective aldosterone synthase inhibitor.
  • In March 2026, Mineralys said the FDA accepted its NDA for lorundrostat in adults with hypertension and set a December 22, 2026 PDUFA target date.
  • In a June 3, 2026 update, Mineralys priced an underwritten common stock offering expecting about $150.0 million in gross proceeds and said it plans to use proceeds to help fund a $200.0 million upfront royalty repurchase.

Finance Related